Subtopic Deep Dive
Genetic Mutations in Uveal Melanoma
Research Guide
What is Genetic Mutations in Uveal Melanoma?
Genetic mutations in uveal melanoma involve driver alterations in GNAQ/GNA11, BAP1, SF3B1, and EIF1AX genes, driving oncogenic MAPK signaling and epigenetic dysregulation.
Targeted sequencing identifies GNAQ/GNA11 mutations in over 80% of uveal melanomas, activating MAPK pathways without BRAF/RAS changes (Zuidervaart et al., 2005, 214 citations). BAP1 mutations correlate with high metastatic risk and loss of protein expression detectable by immunohistochemistry (Kalirai et al., 2014, 187 citations; Abdel-Rahman et al., 2011, 468 citations). Germline BAP1 variants predispose to familial uveal melanoma clusters (Njauw et al., 2012, 249 citations). Approximately 50 papers detail these profiles and prognostic links.
Why It Matters
BAP1 mutation status predicts metastatic risk, guiding surveillance and plaque brachytherapy decisions (Kalirai et al., 2014; Simpson et al., 2013, 328 citations). Germline BAP1 screening identifies hereditary cancer families, enabling early intervention for uveal melanoma, lung adenocarcinoma, and meningioma (Abdel-Rahman et al., 2011). MAPK pathway activation from GNAQ/GNA11 informs targeted therapies, as ipilimumab trials show limited efficacy in metastatic cases (Zimmer et al., 2015, 285 citations; Zuidervaart et al., 2005). Profiling enables prognostic classification into low-risk (SF3B1/EIF1AX) and high-risk (BAP1) groups, impacting survival outcomes.
Key Research Challenges
Distinguishing germline vs somatic BAP1
Germline BAP1 mutations link to familial uveal melanoma and COMMON syndrome, but sequencing struggles to differentiate from somatic events without family pedigrees (Abdel-Rahman et al., 2011, 468 citations; Njauw et al., 2012, 249 citations). Immunohistochemistry detects loss but misses heterozygous cases. Validation requires multi-gene panels.
Correlating mutations to metastasis
BAP1 loss associates with liver metastasis, yet GNAQ/GNA11 ubiquity lacks prognostic power alone (Kalirai et al., 2014, 187 citations; Chattopadhyay et al., 2016, 420 citations). Longitudinal cohorts are small, complicating survival models. Functional assays needed for causality.
Developing MAPK-targeted therapies
GNAQ/GNA11 drive MAPK without BRAF/RAS mutations, evading standard inhibitors (Zuidervaart et al., 2005, 214 citations; Krantz et al., 2017, 387 citations). Ipilimumab fails in metastatic uveal melanoma (Zimmer et al., 2015, 285 citations). Combination epigenetic-MAPK trials lag due to rare incidence.
Essential Papers
Germline <i>BAP1</i> mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers
Mohamed H. Abdel‐Rahman, Robert Pilarski, Colleen M. Cebulla et al. · 2011 · Journal of Medical Genetics · 468 citations
Objective To investigate the potential contribution of germline sequence alterations in the BAP1 gene in uveal melanoma (UM) patients with possible predisposition to hereditary cancer. Design A tot...
Uveal melanoma: From diagnosis to treatment and the science in between
Chandrani Chattopadhyay, Dae Won Kim, Dan S. Gombos et al. · 2016 · Cancer · 420 citations
Melanomas of the choroid, ciliary body, and iris of the eye are collectively known as uveal melanomas. These cancers represent 5% of all melanoma diagnoses in the United States, and their age‐adjus...
Uveal melanoma: epidemiology, etiology, and treatment of primary disease
Benjamin A. Krantz, Nikita Dave, Kimberly M. Komatsubara et al. · 2017 · Clinical ophthalmology · 387 citations
Uveal melanoma (UM) is the most common intraocular malignancy and arises from melanocytes in the iris, ciliary body, or choroid. Early diagnosis and local treatment is crucial, as survival correlat...
The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma
E. Rand Simpson, Brenda L. Gallie, Normand Laperrierre et al. · 2013 · Brachytherapy · 328 citations
Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma
Lisa Zimmer, Julia Vaübel, Peter Mohr et al. · 2015 · PLoS ONE · 285 citations
ClinicalTrials.gov NCT01355120.
Germline BAP1 Inactivation Is Preferentially Associated with Metastatic Ocular Melanoma and Cutaneous-Ocular Melanoma Families
Ching-Ni Jenny Njauw, Ivana K. Kim, Adriano Piris et al. · 2012 · PLoS ONE · 249 citations
Germline BAP1 mutations are associated with a more aggressive OM phenotype and a recurrent phenotypic complex of cutaneous/ocular melanoma, atypical melanocytic proliferations and other internal ne...
The biology of uveal melanoma
Adriana Amaro, Rosaria Gangemi, Francesca Piaggio et al. · 2017 · Cancer and Metastasis Reviews · 232 citations
Reading Guide
Foundational Papers
Start with Abdel-Rahman et al. (2011, 468 citations) for germline BAP1 predisposition; Zuidervaart et al. (2005, 214 citations) for MAPK/GNAQ foundations; Njauw et al. (2012, 249 citations) for metastatic links.
Recent Advances
Chattopadhyay et al. (2016, 420 citations) reviews diagnostics to treatments; Krantz et al. (2017, 387 citations) covers epidemiology and primary therapy; Amaro et al. (2017, 232 citations) details biology.
Core Methods
Targeted NGS for GNAQ/GNA11/BAP1/SF3B1/EIF1AX; immunohistochemistry for BAP1 loss; prognostic classification by mutation class; plaque brachytherapy per Simpson et al. (2013).
How PapersFlow Helps You Research Genetic Mutations in Uveal Melanoma
Discover & Search
Research Agent uses searchPapers('BAP1 germline uveal melanoma') to retrieve Abdel-Rahman et al. (2011, 468 citations), then citationGraph reveals Njauw et al. (2012) cluster and exaSearch uncovers 50+ related germline studies. findSimilarPapers on Kalirai et al. (2014) surfaces BAP1 IHC prognostic papers.
Analyze & Verify
Analysis Agent applies readPaperContent on Zuidervaart et al. (2005) to extract MAPK activation rates, verifyResponse with CoVe cross-checks mutation frequencies against Chattopadhyay et al. (2016), and runPythonAnalysis plots survival curves from BAP1 cohorts using GRADE for evidence strength.
Synthesize & Write
Synthesis Agent detects gaps in BAP1-MAPK therapy links, flags contradictions between germline studies, and uses exportMermaid for mutation pathway diagrams. Writing Agent employs latexEditText for manuscript revisions, latexSyncCitations for 20+ references, and latexCompile for prognostic table PDFs.
Use Cases
"Analyze survival data from BAP1-mutated uveal melanoma cohorts"
Research Agent → searchPapers('BAP1 uveal melanoma survival') → Analysis Agent → readPaperContent(Kalirai 2014) + runPythonAnalysis(pandas Kaplan-Meier plot from extracted cohorts) → GRADE-verified statistical output with p-values and hazard ratios.
"Draft review on GNAQ mutations and MAPK in uveal melanoma"
Synthesis Agent → gap detection(Zuidervaart 2005 + Chattopadhyay 2016) → Writing Agent → latexEditText(intro section) → latexSyncCitations(10 papers) → latexCompile → LaTeX PDF with mutation frequency table.
"Find code for uveal melanoma mutation analysis pipelines"
Research Agent → searchPapers('GNAQ sequencing uveal melanoma') → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → Python scripts for targeted NGS variant calling and BAP1 annotation.
Automated Workflows
Deep Research workflow scans 50+ BAP1/uveal melanoma papers via searchPapers → citationGraph → structured report with GRADE-graded mutation-metastasis links. DeepScan applies 7-step CoVe to verify GNAQ MAPK claims across Zuidervaart (2005) and Krantz (2017). Theorizer generates hypotheses on SF3B1-BAP1 co-mutations from synthesis.
Frequently Asked Questions
What defines genetic mutations in uveal melanoma?
Driver mutations include GNAQ/GNA11 (MAPK activation, >80% cases, Zuidervaart et al., 2005), BAP1 (metastatic risk, Kalirai et al., 2014), SF3B1, and EIF1AX (good prognosis).
What methods detect these mutations?
Targeted sequencing for GNAQ/GNA11/BAP1; immunohistochemistry for BAP1 protein loss (Kalirai et al., 2014); germline panels for familial screening (Abdel-Rahman et al., 2011).
What are key papers on BAP1 in uveal melanoma?
Abdel-Rahman et al. (2011, 468 citations) links germline BAP1 to predisposition; Njauw et al. (2012, 249 citations) to metastasis; Kalirai et al. (2014, 187 citations) to IHC prognostics.
What open problems remain?
Therapies targeting GNAQ-driven MAPK without BRAF/RAS; validating SF3B1/EIF1AX low-risk class in large cohorts; germline-somatic BAP1 distinction in sporadic cases.
Research Ocular Oncology and Treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Genetic Mutations in Uveal Melanoma with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Ocular Oncology and Treatments Research Guide